EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study

Angelo Delmonte, Nicola Gentili iD, Andrea Roncadori iD, Roberta Maltoni iD, Valentina Danesi iD, Pooja Hindocha, Cátia Leal, Stavros Oikonomou iD, Marta Mella iD, Sarah Lay-Flurrie, Gabrielle Emanuel, Caroline Rault und 4 weitere

Cancers · 06.02.2026 · 18 (3) · 538

DOI: 10.3390/cancers18030538 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancers, online erschienen am 06.02.2026. Verfasst von Angelo Delmonte und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment for advanced non-small-cell lung cancer (NSCLC) has evolved substantially over the past decade, necessitating evaluation of real-world treatment patterns and effectiveness before and after the introduction of newer therapies.

Methods

This retrospective cohort study included adult patients initiating a non-curative first-line therapy for advanced NSCLC between 2014 and 2021 at the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), with follow-up through 2022. Overall survival (OS) and real-world progression-free survival from the start date of the first line of therapy for advanced NSCLC were estimated using Kaplan–Meier methods.

Results

Overall, 910 patients were included; at diagnosis, 83% had a de novo diagnosis and 17% had recurrent disease. During the study, 41% of patients received platinum-based chemotherapy alone; 22% received non-platinum-based chemotherapy alone; 21% received anti-programmed death (PD)-(ligand [L])1 immune checkpoint inhibitors (ICIs), alone or with chemotherapy; and 16% received targeted therapy (single-agent tyrosine kinase inhibitors) as first-line therapy for advanced disease. From 2014 to 2021, the proportion of patients receiving first-line anti-PD-(L)1 ICIs increased from 0% to 58% and the proportion of those receiving first-line platinum-based chemotherapy decreased from 65% to 6%. Median (95% CI) OS was 8.2 (7.5–9.2) months; the minimum-to-maximum range of median OS was 6.0–7.4 months from 2014 to 2017 and 8.4–15.9 months from 2018 to 2021. Median OS was numerically longer in patients with recurrent disease versus a de novo diagnosis, first-line targeted versus other therapy, high versus low PD-L1 expression, and non-squamous/other versus squamous histology.

Conclusions

This study provides real-world data further supporting (i) the benefits of precision targeted therapy for patients with advanced NSCLC and actionable genomic alterations and (ii) the positive impact of immunotherapy approvals on the treatment paradigm for advanced NSCLC.

Schlagwörter

Stichwörter der Autor:innen

ItalyOnco-Optimiselocally advancedmetastaticnon-small-cell lung cancer (NSCLC)overall survivalprogression-free survivalreal-world evidencetreatment patterns

Autor:innen und Institutionen

  • Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
  • Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
  • IQVIA Ltd., London W2 1AF, UK.
  • IQVIA Ltd., 2740-266 Porto Salvo, Portugal.
  • IQVIA Ltd., 1303 Sofia, Bulgaria.
  • IQVIA Ltd., 20124 Milan, Italy.

ORCID-Profile: Nicola Gentili, Andrea Roncadori, Roberta Maltoni, Valentina Danesi, Stavros Oikonomou, Marta Mella, Adam Lee, Ilaria Massa

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Delmonte, A., Gentili, N., Roncadori, A., Maltoni, R., Danesi, V., Hindocha, P., Leal, C., Oikonomou, S., Mella, M., Lay-Flurrie, S., Emanuel, G., Rault, C., Glassberg, M. B., Lee, A., Yuan, Y., & Massa, I. (2026). Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study. Cancers, 18(3), 538. https://doi.org/10.3390/cancers18030538

Vancouver

Delmonte A, Gentili N, Roncadori A, Maltoni R, Danesi V, Hindocha P, et al. Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study. Cancers. 2026;18(3):538. doi:10.3390/cancers18030538

BibTeX
@article{Delmonte2026,
  author = {Delmonte, Angelo and Gentili, Nicola and Roncadori, Andrea and Maltoni, Roberta and Danesi, Valentina and Hindocha, Pooja and Leal, Cátia and Oikonomou, Stavros and Mella, Marta and Lay-Flurrie, Sarah and Emanuel, Gabrielle and Rault, Caroline and Glassberg, Mrudula B and Lee, Adam and Yuan, Yong and Massa, Ilaria},
  title = {Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {538},
  doi = {10.3390/cancers18030538}
}
Kostenlos starten →